Whittier, CANCT01954992Now EnrollingIRB Ready

Pancreatic Cancer Clinical Trial in Whittier, CA

Access cutting-edge pancreatic cancer treatment through this phase 3 clinical trial at a research site in Whittier. Study-provided care at no cost to qualified participants.

Sponsored by Eleison Pharmaceuticals LLC.

Quick Self-Assessment

See if you qualify for this Whittier location

Preparing your pre-screening questions…

Expert Care in Whittier

Access pancreatic cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pancreatic cancer treatment provided free

Apply for This Whittier Location

Check if you qualify for this pancreatic cancer clinical trial in Whittier, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Whittier

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Whittier site if eligible
  4. 4Begin participation

About This Pancreatic Cancer Study in Whittier

The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.

Sponsor: Eleison Pharmaceuticals LLC.

Who Can Participate

Inclusion Criteria

At least 18 years of age
Pancreatic adenocarcinoma proven either by histology (surgical biopsy) or cytology (CT- or endoscopic-guided)
Metastatic pancreatic cancer
Disease progression during or after treatment with gemcitabine (alone or in combination with other agents; at regular, not radiosensitizing, doses)
Measurable or nonmeasurable disease by RECIST criteria (at least one target or nontarget lesion)
Recovered from reversible toxicities of prior therapy
ECOG performance status 0-1
All women of childbearing potential and all men must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) from entry into the study through 6 months after the last dose of chemotherapy
Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee

Exclusion Criteria

More than one prior systemic therapy regimen for metastatic pancreatic cancer (radiosensitizing doses of 5-FU or gemcitabine at the time of initial radiotherapy do not count as a prior systemic therapy regimen)
Hormonal therapy, radiation therapy, biologic therapy, chemotherapy or other systemic antitumor therapy for pancreatic cancer within 14 days prior to Cycle 1 Day 1
Insulin-dependent diabetes mellitus (patients with type 2 diabetes controlled with oral glucose lowering agents and the occasional use of insulin are permitted in the study)
Symptomatic brain metastases (baseline CT scan is not required in asymptomatic patients)
Active clinically significant infection requiring antibiotics
Known HIV positive or active hepatitis B or C
Recent (one year) history or symptoms of cardiovascular disease (NYHA Class 2, 3, or 4), particularly coronary artery disease, arrhythmias or conduction defects with risk of cardiovascular instability, uncontrolled hypertension, clinically significant pericardial effusion, or congestive heart failure
No other active malignancies (other than treated non-melanoma skin cancer or treated in situ cancer) within the past year
Major surgery within 3 weeks of the start of study treatment, without complete recovery
Clinically significant abnormalities in laboratory test results (including complete blood count, chemistry panel including electrolytes, and urinalysis)
Hemoglobin \<9 g/dL (may receive transfusion or erythropoietin to maintain)
ANC \<1500/μL
Platelet count \<100,000/μL
Total bilirubin \> 1.5×ULN
AST/ALT \> 2.5-fold above ULN (\>5-fold above ULN if liver metastases)
Phosphorus \< LLN
Potassium \< LLN
Serum creatinine \> 2 mg/dL
Creatinine clearance \< 60 mL/min (calculated by Cockcroft-Gault formula)
Females who are pregnant or breast-feeding
Participation in an investigational drug or device study within 14 days of the first day of dosing on this study
Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study
Any medical history, concurrent disease or concomitant medication which could reasonably predispose the patient to renal insufficiency while on study treatment
Contraindication or unwillingness to undergo multiple CT scans
Unwillingness or inability to comply with the study protocol for any other reason

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Whittier?

Yes, this clinical trial (NCT01954992) has an active research site in Whittier, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Cancer Treatment Options in Whittier, CA

If you're searching for pancreatic cancer treatment options in Whittier, CA, this clinical trial (NCT01954992) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Whittier research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced pancreatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic cancer clinical trials near you to find additional studies recruiting in your area.

More Pancreatic Cancer Trials in Whittier, CA

See all pancreatic cancer clinical trials recruiting in Whittier — not just this study.

Browse Pancreatic Cancer Trials in Whittier →

Browse More Trials by Condition

Pancreatic Cancer TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Whittier?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Whittier, CA